首页> 外文期刊>International journal of clinical oncology >Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients.
【24h】

Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients.

机译:基于非小细胞肺癌患者小活检标本的直接测序法对表皮生长因子受体基因突变的准确性:19例患者的结果分析。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: The importance of an epidermal growth factor receptor (EGFR) gene mutation has been recognized in patients with non-small cell lung cancer (NSCLC), and many reports have indicated that the presence of somatic mutations in the EGFR gene is a strong predictor of both clinical and in vitro sensitivity to EGFR tyrosine kinase inhibitors; thus necessitating the standardization of a mutation screening system based on the sources of tissue samples. METHODS: In this study, we compared the results of EGFR mutation analyses in 19 small biopsy specimens with results obtained in surgical materials from the same patients with NSCLC. We used a laser microdissection method and a direct sequencing method, and we confirmed the accuracy of EGFR mutation analysis with small biopsy specimens. RESULTS: The results obtained from the biopsy specimens were identical to those obtained from the surgical materials in 18 of the 19 patients analyzed. For the 1 patient in whom the results obtained from the two sets of materials were not identical, the number of cancer cells in one bronchoscopic specimen was insufficient to perform analyses of all three exons of interest (i.e., exons 18, 19, and 21), and so only exon 19 was sequenced, and no mutation was demonstrated. CONCLUSION: We conclude that satisfactory accuracy can be achieved by the genomic analysis of a small biopsy specimen from a patient with NSCLC and we note that it is possible to conduct prospective clinical trials that include patient assignment for treatment based on the results obtained.
机译:背景:表皮生长因子受体(EGFR)基因突变的重要性已在非小细胞肺癌(NSCLC)患者中得到公认,许多报道表明,EGFR基因中存在体细胞突变是一个强有力的预测指标对EGFR酪氨酸激酶抑制剂的临床和体外敏感性;因此,有必要基于组织样本的来源对突变筛选系统进行标准化。方法:在这项研究中,我们比较了19例小活检标本中EGFR突变分析的结果与同一名NSCLC患者在手术材料中获得的结果。我们使用了激光显微切割法和直接测序法,并证实了小活检标本中EGFR突变分析的准确性。结果:从活检标本获得的结果与所分析的19例患者中的18例从手术材料获得的结果相同。对于从两组材料获得的结果不一致的1名患者,一个支气管镜标本中的癌细胞数量不足以对所有三个感兴趣的外显子(即外显子18、19和21)进行分析。 ,因此仅对第19外显子进行了测序,未发现突变。结论:我们得出结论,通过对来自NSCLC患者的小型活检标本进行基因组分析,可以达到令人满意的准确性,并且我们注意到,有可能进行前瞻性临床试验,其中包括根据所得结果指定患者的治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号